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Recent work has cast a spotlight on the brain as a nutrient-sensing organ that regulates the body’s
metabolic processes. Here we discuss the physiological and molecular mechanisms of brain lipid
sensing and compare these mechanisms to liver lipid sensing. A direct comparison between the
lipid-sensing mechanisms in the brain and liver reveals similar biochemical/molecular but opposing
physiological mechanisms in operation. We propose that an imbalance between the lipid-sensing
mechanisms in the brain and liver may contribute to obesity-associated type 2 diabetes.The incidence of obesity and diabetes
has reached epidemic proportions,
and many laboratories worldwide have
dedicated major efforts and resources
toward elucidating the potential mech-
anisms underlying the development of
these diseases. Two critical features
of obesity and diabetes are hyperpha-
gia and hyperglycemia. The central
nervous system (CNS) has been dem-
onstrated to regulate food intake (Cota
et al., 2006; Flier, 2004; Friedman,
2000; Kahn et al., 2005; Schwartz and
Porte, 2005; Wolfgang and Lane,
2006). In addition, there is growing evi-
dence indicating that the CNS (specifi-
cally the hypothalamus) senses hor-
mones and nutrients to regulate
glucose homeostasis (Bence et al.,
2006; Coppari et al., 2005; Flier, 2004;
Gelling et al., 2006; Inoue et al., 2006;
Kievit et al., 2006; Lam et al., 2005a,
2005b, 2005c; Obici et al., 2002a,
2002b, 2003; Schwartz and Porte,
2005). This perspective focuses on the
physiological and molecular mecha-
nisms of glucose regulation by CNS
lipid sensing and compares the asso-
ciated sensing mechanisms to liver
lipid sensing.
Brain/Liver Lipid Sensing
and Liver Insulin Action
Intracerebroventricular (i.c.v.) admin-
istration of oleic acids (a type of long-
chain fatty acid [LCFA]) for 6 hr was
first demonstrated to lower plasma
insulin and glucose levels under basal
physiological conditions in rodents(Obici et al., 2002a). To assess
whether the decline in blood glucose
levels induced by i.c.v. oleic acids
corresponded to a change in periph-
eral insulin action, the i.c.v. adminis-
tration protocol was combined with
a pancreatic (basal insulin) euglycemic
clamp technique. Under these experi-
mental conditions, i.c.v. oleic acid
administration reduced hepatic glu-
cose production (GP) (Obici et al.,
2002a).
Carnitine palmitoyltransferase-1
(CPT-1) regulates the transportation
of fatty acids into the mitochondria
for b-oxidation. Chemical inhibition
of CPT-1 in the mediobasal hypo-
thalamus increases esterified LCFA
(LCFA-CoA) (Obici et al., 2003). Eleva-
tion of hypothalamic LCFA-CoA levels
(via CPT-1 inhibition) for 6 hr sup-
presses GP to an extent similar to
short-term i.c.v. oleic acid administra-
tion (Obici et al., 2003). However,
administration of ATP-sensitive potas-
sium (KATP) channel blockers abol-
ishes the suppressive effects of both
i.c.v. oleic acid administration and
hypothalamic CPT-1 inhibition (Obici
et al., 2002a; Pocai et al., 2005b), while
activation of central KATP channels
alone (via hypothalamic diazoxide ad-
ministration) suppresses GP (Pocai
et al., 2005a). Taken together, these
initial findings by Rossetti and col-
leagues suggest that short-term hypo-
thalamic accumulation of LCFA-CoAs
and the activation of KATP channels
play an important role in CNS lipidCell Metabolismsensing and subsequent suppression
of GP.
By contrast, it has been demon-
strated in rodents, dogs, and humans
that short-term elevation of LCFAs in
the blood induces liver insulin resis-
tance. Specifically, intravenous (i.v.)
lipid administration increases GP dur-
ing hyperinsulinemic-euglycemic clamp
conditions (Boden et al., 1994; Lam
et al., 2002, 2003b; Lewis et al., 1997;
Rebrin et al., 1996; Sindelar et al.,
1997). The elevation of GP is asso-
ciated with increased hepatic glyco-
genolysis (Boden et al., 2002). In paral-
lel, transgenic mice with liver-specific
overexpression of lipoprotein lipase
(the rate-limiting enzyme in triglyceride
hydrolysis, which releases free fatty
acids [FFA] and glycerol) develop he-
patic insulin resistance (Kim et al.,
2001). These mice manifest defects
in insulin activation of hepatic IRS-
2-associated phosphatidylinositol
3-kinase (PI3K) activity. These data
indicate direct impairment of liver insu-
lin action by lipids.
One proposed molecular mecha-
nism underlying these effects is the
accumulation of LCFAs in liver cells,
followed by conversion to and accu-
mulation of LCFA-CoA as the active
species. This model is supported by
the observation that increases in he-
patic LCFA-CoA and diacylglycerol
(DAG, an esterification product of
LCFA-CoA) induced by high-fat feed-
ing or i.v. lipid infusion are associated
with liver insulin resistance (Boden6, August 2007 ª2007 Elsevier Inc. 99
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PerspectiveFigure 1. The Balance of Lipid-Sensing Mechanisms in the Brain and the Liver
(A) Lipid sensing in the brain reduces glucose production (GP). In contrast, lipid sensing in the liver
reduces liver insulin action, thereby promoting GP. Under normal conditions, the opposing effects
of lipid sensing in these two vital organs achieve a balance in GP regulation, contributing to plasma
glucose homeostasis.
(B) The balance between lipid sensing in the brain and in the liver is disrupted in obesity-associated
diabetes, leading to an elevation of GP.et al., 2005; Samuel et al., 2004).
Elevated levels of DAG and malonyl-
CoA (an allosteric inhibitor of CPT-1)
are also associated with glucose-
induced liver insulin resistance (Krae-
gen et al., 2006). Since CPT-1 is
responsible for b-oxidation in the
transport of FFA into the mitochondria,
inhibition of CPT-1 activity would
result in the accumulation of LCFA-
CoA (McGarry et al., 1977; Ruderman
et al., 1999). Indeed, inhibition of liver
CPT-1 with etomoxir induces liver
insulin resistance (Dobbins et al.,
2001). These data collectively indicate
that short-term elevation of liver LCFA-
CoA or LCFA-CoA-derived DAG
increases GP under hyperinsuline-
mic-euglycemic clamp conditions.
In summary, short-term accumula-
tion of LCFA-CoAs in the brain reduces
GP, whereas short-term increases in
liver LCFA-CoAs increase GP. The
relative contributions of these two
mechanisms to GP regulation is not
known and may differ in various phys-
iological and pathophysiological con-
ditions. However, taken together, the
data pose an interesting paradigm.
We propose that the lipid-sensing
mechanisms in both the brain and liver
balance GP regulation and maintain
plasma glucose homeostasis (Fig-
ure 1A). More importantly, diet-in-100 Cell Metabolism 6, August 2007 ª200duced obesity impairs this balance
and increases GP, progressively lead-
ing to type 2 diabetes (Figure 1B).
An Imbalance in Brain/Liver
Lipid-Sensing Mechanisms
in Experimental Models
Could the manipulation of lipid-sens-
ing mechanisms in the brain and/or
liver affect the balance of GP regula-
tion and disrupt plasma glucose
homeostasis? If so, what is the relative
contribution of brain and liver lipid
effects on GP and plasma glucose
levels? To address these questions
in vivo, we employ an experimental
model in which short-term elevation
of circulating LCFAs increases liver
gluconeogenesis while inhibiting gly-
cogenolysis. This balances GP regula-
tion under basal insulin clamp condi-
tions (Chen et al., 1999; Chu et al.,
2002; Lam et al., 2005b). The first
strategy abolishes the hypothalamic
lipid-sensing mechanisms in this in
vivo model and tests whether this
disruption leads to an increase in GP.
The experimental approach targets
the prevention of either the accumula-
tion of LCFA-CoAs or the activation of
the KATP channels in the hypothala-
mus, since both have been demon-
strated to play an important role in
CNS lipid sensing (see above). It has7 Elsevier Inc.been reported that circulating LCFAs
cross the blood-brain barrier (Miller
et al., 1987), and i.v. administration of
LCFAs for 4 hr doubles hypothalamic
LCFA-CoA levels (Lam et al., 2005b).
When the hypothalamic LCFA esteri-
fication pathway is inhibited via ad-
ministration of triacsin C (an inhibitor
of acyl-CoA synthase), the ability of
circulating LCFAs to increase hypo-
thalamic LCFA-CoAs is negated (Lam
et al., 2005b). This negation has also
been observed in rats overexpressing
hypothalamic malonyl-CoA decarbox-
ylase (MCD) (He et al., 2006). More
importantly, both of these approaches
result in an increase in hepatic gly-
cogenolysis and GP in response to
i.v. lipid infusion (He et al., 2006; Lam
et al., 2005b). Furthermore, central
pharmacological blockade and ge-
netic disruption of hypothalamic KATP
channels markedly elevate hepatic
glycogenolysis and GP in response to
systemic lipid infusion (Lam et al.,
2005b). Together, these initial findings
show that disruption of hypothalamic
lipid-sensing mechanisms leads to an
imbalance of GP regulation.
Does the abolition of liver lipid-sens-
ing mechanisms disrupt GP regulation
in an opposing manner in order to
lower GP? Unfortunately, no studies
to date have addressed this working
hypothesis in the hyperlipidemic basal
insulin clamp model described above.
However, other approaches to abolish
liver lipid-sensing mechanisms have
included lowering liver lipid (i.e.,
LCFA-CoA) accumulation or inhibiting
subsequent causative insulin resis-
tance mechanisms (i.e., protein kinase
C [PKC] activation) under hyper-
lipidemic-hyperinsulinemic clamp con-
ditions. For example, liver MCD
overexpression results in decreased
malonyl-CoA levels and increased lipid
oxidation, which ameliorates high-fat-
diet-induced liver insulin resistance
(An et al., 2004). Antisense oligodeox-
ynucleotide inhibition of liver acetyl-
CoA carboxylase, an enzyme that
stimulates the production of malonyl-
CoA from acetyl-CoA, lowers hepatic
levels of malonyl-CoA, LCFA-CoA,
and DAG in rats fed a high-fat diet.
This also reverses diet-induced he-
patic insulin resistance (Savage et al.,
2006).
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LCFA-CoA Level GP
Free fatty acid influx
Brain (Lam et al., 2005b; Obici et al., 2002a) [ Y
Liver (Kim et al., 2001) [ [
CPT-1 inhibition
Brain (Obici et al., 2003) [ Y
Liver (Dobbins et al., 2001) [ [
MCD overexpression
Brain (He et al., 2006) Y [
Liver (An et al., 2004) Y YIncreased abundance of LCFA-
CoAs or LCFA-CoA-derived DAG in-
duces hepatic insulin resistance. This
is possibly through the activation of
liver PKC (Boden et al., 2005; Lam
et al., 2002; Samuel et al., 2004).
Subsequent work has shown that
lipid metabolites activate liver PKC
(Boden et al., 2005; Chen et al., 2006;
Collins et al., 2006; Lam et al., 2002;
Samuel et al., 2004). Furthermore, ac-
tivation of PKC (a serine/threonine
kinase) can phosphorylate IRS-2, re-
ducing the ability of IRS-2 to undergo
tyrosine phosphorylation, which is in
turn needed for the recruitment and
activation of downstream signaling
pathways in the liver (Samuel et al.,
2004). This scenario would result in
liver insulin resistance (Kido et al.,
2000; Kubota et al., 2000; Withers
et al., 1998). In fact, work from inde-
pendent laboratories has demon-
strated that lipid- or high-fat-diet-
induced hepatic insulin resistance is
associated with activation/membrane
translocation of hepatic PKC-d and -3
in vivo (Boden et al., 2005; Lam et al.,
2002; Samuel et al., 2004). More-
over, antisense oligodeoxynucleotide
downregulation of liver PKC-3 expres-
sion prevents diet-induced liver insulin
resistance (Samuel et al., 2007). Taken
together, these data show that a dis-
ruption of liver lipid-sensing mecha-
nisms also leads to an imbalance in
the regulation (in this case suppres-
sion) of GP under hyperinsulinemic
clamp conditions.
We propose, however, that a pan-
creatic basal insulin (and not hyperin-
sulinemic) clamp condition is required
to directly assess the balance andrelative contributions of liver and brain
lipid-sensing mechanisms. This is
mainly because lipid-sensing mecha-
nisms in the brain do not appear to
inhibit GP during hyperinsulinemia.
Circulating LCFAs increase GP under
hyperinsulinemic (Boden et al., 1994;
Lam et al., 2003a; Lewis et al., 1997;
Rebrin et al., 1996; Sindelar et al.,
1997) but not pancreatic (basal insulin)
clamp conditions (Chen et al., 1999;
Chu et al., 2002; Lam et al., 2005b). In-
terestingly, hypothalamic lipid-sensing
mechanisms are impaired in diet-
induced obesity, a condition that is
also associated with hyperinsulinemia
(see below) (Morgan et al., 2004). To
directly assess the relative contribu-
tion that liver lipid-sensing mecha-
nisms make to the regulation of GP,
the underlying mechanisms responsi-
ble for lipid-induced liver gluconeo-
genesis will first need to be examined
(Collins et al., 2006; Yoon et al.,
2001). Although the mechanisms
controlling lipid-induced liver gluco-
neogenesis remain unknown, short-
term incubation of oleate has been
found to activate PKC-d in hepato-
cytes (Chen et al., 2006), and this
hepatocyte PKC-d activation has
been reported to mediate lipid-
induced gluconeogenesis (Collins
et al., 2006). Thus, lowering liver LCFA-
CoA accumulation (i.e., liver MCD
overexpression or ACC downregula-
tion) and inhibiting hepatic PKC
activation under the hyperlipidemic
pancreatic (basal insulin) clamp condi-
tion is a favored approach to selec-
tively evaluate the relative contribution
of liver versus brain lipid-sensing
mechanisms.Cell MetabolismThe evaluation of the selective and
relative contributions of lipid-sensing
mechanisms in the brain and liver is
therefore ideally performed under pan-
creatic (basal insulin) clamp condi-
tions, which eliminate potential con-
founding effects of hyperinsulinemia
in the brain. However, the basal insulin
clamp experimental model would not
be suitable for evaluating any potential
regulatory effects of the CNS lipid-
sensing mechanisms on the rate of in-
sulin-stimulated peripheral glucose
uptake. In addition, potential regu-
latory effects of CNS lipid-sensing
mechanisms on insulin and glucagon
secretion also cannot be assessed.
This is because somatostatin is admin-
istered during the clamp studies in or-
der to inhibit endogenous insulin and
glucagon secretion. Theseclamp tech-
niques, however, do enable selective
evaluation of the ability of the lipid-
sensing mechanisms to regulate body
glucose metabolism independent of
changes in circulating glucoregulatory
hormones at basal levels. This is criti-
cal, given that insulin can indepen-
dently signal the brain to regulate GP
(Inoue et al., 2006; Obici et al., 2002b;
Pocai et al., 2005a), although the cen-
tral effect of insulin has recently been
questioned (Edgerton et al., 2006).
Future studies are needed to ad-
dress the selective and relative regula-
tion of GP and plasma glucose levels
by lipid-sensing mechanisms in the
basal (unclamped) conditions as well.
Preliminary findings indicate that
hypothalamic nutrient-sensing mech-
anisms appear to regulate plasma glu-
cose levels under basal (unclamped)
conditions since direct administration
of either oleic acid or glucose into the
hypothalamus lowers plasma glucose
levels (Lam et al., 2005a; Obici et al.,
2002a). This glucose-lowering effect
by the brain is retained for at least
4 hr in response to the central adminis-
tration protocol and is associated with
changes in the plasma level of gluco-
regulatory hormones. These data
indicate that the potential regulation
of insulin and glucagon secretion by
the CNS could play a role in regula-
ting GP and maintaining glucose
homeostasis. Future experiments
designed to address these issues
are needed.6, August 2007 ª2007 Elsevier Inc. 101
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PerspectiveFigure 2. Mechanisms of Lipid and Glucose Sensing in the Brain and the Liver
Circulating lipids enter the brain and liver and are acted upon by the converting enzyme acyl-coA synthetase (ACS), increasing the level of long-chain
fatty acid (LCFA)-CoAs. Inhibition of carnitine palmitoyltransferase-1 (CPT-1) increases the amount of LCFA-CoAs in the brain and reduces GP, while
CPT-1 inhibition in the liver increases GP. By contrast, decreasing LCFA-CoA levels via overexpression of malonyl-CoA decarboxylase (MCD) in the
brain increases GP, and MCD overexpression in the liver reduces GP in lipid-challenged rodents. Similar biochemical and physiological mechanisms
are proposed for glucose sensing in both the brain and the liver. After entering the brain and liver, glucose ismetabolized into acetyl-CoA andmalonyl-
CoA, leading to an elevation of LCFA-CoAs. Acetyl-CoA carboxylase (ACC) converts acetyl-CoA tomalonyl-CoA. This subsequent elevation of LCFA-
CoAs reduces GP in the brain and increases GP in the liver.Comparison of Brain and Liver
Lipid-Sensing Mechanisms
in Experimental Models
A thorough examination of biochemi-
cal pathways involved in liver and brain
response to lipid sensing reveals a
similar biochemical/molecular profile,
but with opposing physiological mech-
anisms (Table 1). First, mice with liver-
specific overexpression of lipoprotein
lipase exhibit an accumulation of liver
LCFA-CoAs, with reduced liver insulin
action and increased GP (Kim et al.,
2001). In contrast, accumulation of
hypothalamic LCFA-CoAs via lipid
administration reduces GP (Lam
et al., 2005b; Obici et al., 2002a). Sec-
ond, inhibition of liver CPT-1 (which
elevates LCFA-CoA levels) induces
liver insulin resistance and increases
GP (Dobbins et al., 2001), whereas
selective inhibition of hypothalamic
CPT-1 reduces GP (Obici et al.,
2003). Third, selective overexpression
of MCD in the liver (which lowers
malonyl-CoA and LCFA-CoA levels)
increases liver insulin action and re-
duces GP in mice fed a high-fat diet
(An et al., 2004), whereas selective102 Cell Metabolism 6, August 2007 ª20overexpression of MCD in the hypo-
thalamus increases GP in response
to lipid infusion (He et al., 2006). Al-
though these models differ in some re-
spects (i.e., transgenic versus lipid
versus high-fat diet), these findings
collectively indicate that an accumu-
lation of LCFA-CoAs in the liver in-
creases GP and reduces GP in the
brain.
The fact that LCFA-CoAs are the
potential signaling molecules in both
the liver and brain for GP regulation
fosters two observations/speculations
(Figure 2). First, the liver and brain
share biochemical/molecular path-
ways but have opposing physiological
mechanisms linked to glucose sens-
ing. The metabolism of glucose via
glycolysis forms malonyl-CoA, which
inhibits CPT-1 and elevates LCFA-
CoAs. Accordingly, influx of glucose
into the liver, pancreas, and muscle
has been demonstrated to increase
malonyl-CoA/LCFA-CoA levels (Ru-
derman and Prentki, 2004). A simi-
lar biochemical pathway has been
proposed for glucose sensing in the
hypothalamus (Lam et al., 2005c). Fur-07 Elsevier Inc.thermore, direct administration of
glucose into the hypothalamus indeed
reduces GP (Lam et al., 2005a),
whereas elevated liver malonyl-CoA
and LCFA-CoA following systemic glu-
cose infusion induce liver insulin resis-
tance and increase GP (Kraegen et al.,
2006). Second, the biochemical/
molecular pathway implicated in liver
lipid-induced insulin resistance in-
cludes molecules that may mediate
the activation of hypothalamic LCFA-
CoA-induced KATP channels that con-
sequently reduce GP. Does a PKC-
mediated biochemical pathway play
a role in hypothalamic lipid-sensing
mechanisms? Toll-like receptor 4
(TLR4) has recently been implicated
in lipid-induced insulin resistance,
and TLR4 is expressed in both the liver
and brain (Shi et al., 2006). Does the
TLR4 signaling pathway in both the
brain and liver play a role in GP regula-
tion? Finally, LCFAs with different
degrees of unsaturation have been im-
plicated in the differential impairment
of insulin action (Clore et al., 2004;
Dobbins et al., 2002; Storlien et al.,
1991; Xiao et al., 2006). Could this
Cell Metabolism
Perspectivereflect the inability of some specific
types of fatty acids to signal the brain
to inhibit GP? To date, oleic acids
(Obici et al., 2002a) and Intralipid
(26% oleic acid, 50% linoleic acid,
9% linolenic acid, 10% palmitic acid,
and 3.5% stearic acid) (Lam et al.,
2005b) have been implicated in the
signaling that regulates GP in the
hypothalamus. Future studies are
needed to characterize the metabolic
effects of specific fatty acids in the
liver and brain.
An Imbalance in Brain/Liver
Lipid-Sensing Mechanisms
in Obesity and Diabetes
The characterization of GP regulation
in experimental models is important.
However, a more urgent question
needs to be addressed: Does the
imbalance of brain/liver lipid-sensing
mechanisms contribute to the devel-
opment of liver insulin resistance in
the context of obesity-associated
diabetes? In other words, could liver
lipid-induced gluconeogenesis lead
to an imbalance and elevation of GP
because of an inability of brain lipid
mechanisms to inhibit GP in obesity
and diabetes (Figure 1B)? To address
this question in vivo, hypothalamic
lipid sensing mechanisms were tested
in overfed rats. Male Sprague-Dawley
rats double their caloric intake and
develop hyperinsulinemia and liver in-
sulin resistance when fed a lard-
enriched diet for 3 days (Morgan
et al., 2004). Strikingly, i.c.v. oleic
acid infusion in these rats failed to
lower GP (Morgan et al., 2004). More
importantly, when LCFAs were admin-
istered i.v. in this overfed model,
inducing liver gluconeogenesis as a
response, GP was elevated in par-
allel with decreased hypothalamic
LCFA-CoA accumulation (Lam et al.,
2005b). Inhibition of hypothalamic
CPT-1 restores LCFA-CoA accumula-
tion to normal conditions in this lipid-
challenged overfed model and, more
importantly, restores the balance of
GP regulation during the pancreatic
basal insulin clamp (Pocai et al.,
2006). Taken together, these initial
studies by Rossetti and colleagues
suggest that the inability of the brain
to sense lipids in diet-induced obesity
is due in part to increased hypotha-lamic CPT-1 activity and lowered
malonyl-CoA levels, which conse-
quently lead to an imbalance in GP
regulation and the development of liver
insulin resistance (Pocai et al., 2006). It
is interesting to note that hypothalamic
lipid-sensing mechanisms are im-
paired not only in diet-induced hyper-
insulinemia and obesity (Lam et al.,
2005b; Morgan et al., 2004; Pocai
et al., 2006) but also potentially in
hyperinsulinemic-euglycemic clamp
experimental models (see above)
(Boden et al., 1994; Lam et al.,
2003a; Lewis et al., 1997; Rebrin
et al., 1996; Sindelar et al., 1997).
These observations suggest that hy-
perinsulinemia (in the presence of
hyperlipidemia) may hinder hypotha-
lamic lipid sensing by interfering with
the accumulation of LCFA-CoA or
with downstream signaling pathways.
This hypothesis remains to be investi-
gated. Finally, the balance of GP regu-
lation has only been tested so far in
a 3 day high-fat-diet model. More
work is needed to better characterize
the balance of GP regulation in obesity
and diabetes. Specifically, this work-
ing hypothesis could be tested in
prolonged high-fat-diet and lipid-
induced obesity/insulin resistance
models or in partial pancreatecto-
mized and streptozotocin-induced
diabetic models. Such data would al-
low improved characterization and
elucidation of the pathways underlying
the balance of lipid-sensing mecha-
nisms in the brain and liver under path-
ological conditions.
Conclusions
The global prevalence of obesity and
diabetes is increasing at an alarming
rate, and elevation of lipids has been
posited as a causative link between
obesity, insulin resistance, and diabe-
tes. We propose that lipid-sensing
mechanisms increase GP in the liver
and decrease GP in the brain to
achieve a balance in GP regulation.
More importantly, we suggest that
this balance is disturbed in obesity,
leading to the development of liver
insulin resistance and progression to
type 2 diabetes. Based on these
hypotheses, therapeutic approaches
aimed at reversing diet-induced liver
insulin resistance should include bothCell Metabolisma lowering of lipid accumulation in the
liver as well as restoration of lipid
accumulation in the brain.
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